Oncology | CHOP Research Institute


The purpose of this study is to evaluate the efficacy of Cart 19 cells therapy as measured by overall remission rate, which includes Complete Remission and Complete Remission with incomplete blood count recovery assessment in infants to adults.

This study involves taking a study drug called lurbinectedin. The overall goal of this study is to see if different doses of lurbinectedin are safe and effective at treating children and young adults with recurrent or relapsed solid tumors, including Ewing Sarcoma.

Published on
Jan 27, 2023
By studying the molecular basis of pediatric thyroid cancer, Dr. Franco seeks to improve outcomes and quality of life for patients.

The study will enroll male and female patients between 2 years to 25 years of age with sickle cell disease or beta thalassemia major, who do not have a matched related donor, and their doctor feels their condition should be treated with hematopoietic stem cell transplantation (HSCT).

The purposes of this study is to examine efficacy of the IDEAL2 (Improving Diet and Exercise in ALL) caloric restriction and activity intervention integrated into HR B-ALL induction to reduce incidence of end of induction (EOI) MRD ≥0.01%.

The goal of this observational study is to describe the safety and effectiveness of larotrectinib in patients with locally advanced or metastatic TRK fusion cancer for whom a decision to treat with larotrectinib has been made before enrollment.

This study involves taking a study drug called Lutathera.

The purpose of the Phase 2 portion of this study is to evaluate the safety and efficacy of the study drug called palbociclib when given in combination with two other drugs (temozolomide and irinotecan) in patients with Ewing sarcoma.

The purpose of this study is to find out what is the right dose of copanlisib in children and adolescents, and if your disease responds to this new drug.